

Studies Towards the Total Synthesis of Rapamycin: Preparation of the Cyclohexyl C₃₃-C₄₂ Fragment and Further Coupling to Afford the C₂₂-C₄₂ Carbon Unit.


Cyrille Kouklovsky, Steven V. Ley* and Stephen P. Marsden

Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.

Abstract: A short and stereoselective synthesis of the C₃₃-C₄₂ fragment **3** of rapamycin and its coupling with the previously prepared C₂₂-C₃₂ fragment **2** is described. The synthesis of **3** involves the preparation of enantiomerically enriched methylene cyclohexane derivative **7**, followed by side-chain elaboration. The coupling is made by reaction of the lithio anion of the dithioacetal monosulfone **11** on the epoxide **3**.

In the previous paper,¹ we reported our general synthetic plan towards the potent immunosuppressive agent rapamycin.² We also described the synthesis of the C₂₂-C₃₂ portion **2** of this molecule. Here we discuss the preparation of the C₃₃-C₄₂ cyclohexyl epoxide fragment **3** and its subsequent coupling with **2** to afford a fully functionalized C₂₂-C₄₂ carbon framework **4** necessary for later transformation to the natural product (Scheme 1).


Scheme 1



For the synthesis of **3**, we have developed a method for the stereoselective synthesis of methylene cyclohexane derivatives as key intermediates, involving intramolecular reaction of an allylsilane with an oxonium cation generated from an α -alkoxysulfone.³ Thus, the previously prepared β -ketosulfone **5** was

subjected to asymmetric reduction using borane.DMS and 10% of the CBS oxaborolizidine catalyst⁴ to give the β -hydroxysulfone **6** along with the *syn* isomer in the ratio of 1:2 in quantitative yield.⁵ The enantiomeric excess of the *anti* isomer was determined to be of 80%.⁶ The unwanted *syn* isomer could be readily oxidized (PDC, DCM) to **5** for recycling. The *anti* isomer **6**, after silylation with *tert*-butyldimethylsilyl trifluoromethane sulfonate (TBS triflate) was treated with a solution of tin tetrachloride in dichloromethane at -78°C to give **7** in 60% overall yield, as a 5:1 ratio of *trans*/*cis* isomers. Hydroboration of **7** to the alcohol **8** proceeded well and the minor stereoisomer from cyclization was removed at this stage.⁷ Following oxidation of **8** using Swern conditions⁸ to give the intermediate aldehyde, addition (-)-(*E*) crotyl diisocampheylborane afforded, after oxidative work-up, **9** as the major product in 64% yield, readily separable from any contaminating isomers. The hydroxyl group in the side chain is ideally placed to direct the final epoxidation reaction using standard conditions⁹ (TBHP, VO(acac)₂) to give **10** as a 4:1 mixture of diastereoisomers readily separable by chromatography. The major isomer was further deoxygenated *via* its thionocarbonate derivative by reduction with tributyltin hydride¹⁰ to give the desired epoxide **3**¹¹ in 70% yield for two steps (Scheme 2).


Scheme 2



a: BH_3/DMS , 10% CBS, THF, 100%; *syn*/*anti*: 2:1; *ee anti*: 80%; b: TBSOTf, Pyridine, DMAP, CH_2Cl_2 , 0°C ; c: SnCl_4 , CH_2Cl_2 , -78°C , 60% overall; d: 9-BBN, THF, 0° to 25°C , H_2O_2 , NaOH, 80%, separation of isomers; e: $(\text{COCl})_2$, DMSO, Et_3N , CH_2Cl_2 , 90%; f: (-)-(*E*)-(IPc)₂-CH₂-CH=CH-CH₃, THF/ Et_2O , -78°C , H_2O_2 , OH⁻, separation of diastereoisomers; 70%; g: ^tBuOOH, VO(acac)₂, CH_2Cl_2 , 90%; h: ⁿBuLi, THF, -20°C , ClC(=S)OPh, 85%; i: ⁿBu₃SnH, AIBN, Benzene, reflux, 80%.


For the coupling of the components, we have chosen to use the methodology of Tokate¹² and co-workers whereby α -sulfenyl sulfones are used as acyl anion equivalents. Accordingly, sulfone **2** was deprotonated (^tBuLi, THF, -78°C) and treated with dimethyl disulfide to give **11** as a 1:1 mixture of diastereoisomers (81% yield) which was not purified but directly used in the next reaction. Thus, deprotonation of **11** (^tBuLi, THF, -78°C), addition of a solution of the epoxide **3** (1.1 eq.) followed by addition of boron trifluoride etherate (BF_3 etherate, 2 eq.) gave after 2 h (-78° to 0°C) the coupled product **4** in an unoptimised 46% yield (Scheme 3).

Scheme 3



It is interesting to notice that upon work-up **4** is obtained with the ketone function already deprotected¹³. According to the work of Tokate, the hydrolysis of dithioketal monosulfones requires stronger conditions and long reaction times (CuCl_2 , SiO_2 or anodic hydrolysis). In our case, we attribute the easy hydrolysis to the presence of BF_3 etherate which can hydrolyse *in situ* the dithioketal to thioketone derivative (Scheme 4). This explains the need for two equivalents of BF_3 etherate in the coupling reaction.

Scheme 4



In conclusion, in a short sequence of reactions, the epoxide **3** has been prepared and coupled to a derivative of **2** to afford the $\text{C}_{22}\text{-C}_{42}$ carbon framework of rapamycin. Further functional group manipulation and completion of the synthesis are currently under investigation and will be reported in due course.

Acknowledgements: We thank the SERC for a Quota Award and Zeneca Agrochemicals for a postgraduate scholarship (to SPM) and BP for a Research Professorship Endowment (to SVL). Additional financial support from Pfizer Central Research is also gratefully acknowledged.

References and footnotes

- Anderson, J.C., Ley, S.V. and Marsden, S.P., see previous paper and references therein.
- Isolation: Vezina, C., Kudelski, A. and Sehgal, S.N., *J. Antibiot.*, **1975**, *28*, 721; Sehgal, S.N., Baker, H. and Vezina, C., *J. Antibiot.*, **1975**, *28*, 727; structure: Swindells D.C.N., White P.S. and Findlay J.A., *Can. J. Chem.*, **1978**, *56*, 2491; Findlay J.A. and Radics L., *Can. J. Chem.*, **1980**, *58*, 579.
- Ley, S.V. and Kouklovsky, C., *Tetrahedron*, in press.
- Corey, E.J., Bashki, R.K. and Shibata, S., *J. Am. Chem. Soc.*, **1987**, *109*, 5551; this catalyst was derived from (+) L-proline and prepared according to the procedure of Merck & Co: Mathre, D.J., Jones, T.K., Xavier, L.C., Blacklock, T.J., Reamer, R.A., Mohan, J.J., Tirner Jones, E.T., Hoogsteen, K., Baum, M.W. and Grabowski, E.J.J., *J. Org. Chem.*, **1991**, *56*, 751.
- Satisfactory spectral and analytical data were obtained for all the proposed structures. Complete experimental data for intermediates **5**, **6** and **7** (as racemic mixtures) can be found in ref. 3.
- The enantiomeric excess of *anti* **6** was difficult to determine by derivatization due to the low reactivity of the hydroxyl function. It was found easier to determine the *ee* on a later intermediate.
- The *ee* of **8** was determined to be ca. 80% by ¹⁹F NMR analysis of the Mosher's ester derivative. Desilylation of **8** (HF, CH₃CN) furnished (*1R 2R 4R*) 4-hydroxymethyl 2-methoxy 1-cyclohexanol, [α]_D -45 (*c* = 0.6, CHCl₃), which is a degradation product of FK-506 and the optical rotation of which is reported to be -57 (*c* = 0.5, CHCl₃): Tanaka, H., Kuroda, A., Murasawa, H., Hatanaka, H., Kino, T., Goto, T., Hashimoto, M. and Taga, T., *J. Am. Chem. Soc.*, **1987**, *109*, 5031.
- Mancuso, A.J. and Swern, D., *Synthesis*, **1981**, 165.
- Mihelich, E.D., Daniels, K. and Eickoff, D.J., *J. Am. Chem. Soc.*, **1981**, *103*, 7690.
- Robins, M.J. and Wilson, J.S., *J. Am. Chem. Soc.*, **1981**, *103*, 932.
- Data for epoxide **3**: [α]_D = -20.95 (*c* = 0.99, CHCl₃); ¹H NMR (400 MHz, CDCl₃, rapamycin numbering): δ (ppm): 3.39 (3H, s, OMe), 3.38 (1H, partially obscured m, C₃₉-H), 2.89 (1H, dt, *J* = 9 and 2 Hz, C₄₀-H), 2.67 (2H, m, C₃₃-H x 2), 2.45 (1H, ddd, *J* = 6, 5 and 3, C₃₄-H), 2.02 (1H, dt, *J* = 9 and 2, C₃₈-H ax.), 1.82 (1H, m, C₃₅-H), 1.67 (1H, m, one of C₄₁-H), 1.48 (1H, m, one of C₄₂-H), 1.45-1.35 (3H, m, one of C₃₆-H, C₃₇-H and one of C₄₁-H), 1.22 (1H, m, one of C₃₆-H), 0.91 (1H, partially obscured m, one of C₄₂-H), 0.90 (3H, d, *J* = 7 Hz, C₃₅-Me), 0.88 (9H, s, ^tBuSi), 0.83 (1H, partially obscured m, C₃₈-H eq.), 0.07 and 0.05 (6H, 2s, Me₂Si); ¹³C NMR (100 MHz, CDCl₃): δ (ppm): 84.5 (C₃₉), 75.7 (C₄₀), 58.0 (C₃₄), 57.2 (OMe), 45.5 (C₃₃), 41.7 (C₃₆), 36.6 (C₃₈), 33.9 (C₄₁), 33.5 (C₃₇), 33.2 (C₃₅), 31.3 (C₄₂), 25.9 ((CH₃)₃-C-Si), 18.2 (Me₃-C-Si), 16.1 (C₃₅-CH₃), -4.5 and -4.7 (Me₂-Si); Mass (EI): *m/z*: 329 (MH⁺), 328 (M⁺), 313 (M-Me), 271, 239, 165, 147, 135, 121, 105, 89 (100%), 73; HRMS calculated for C₁₈H₃₆O₃Si; Calc: 328.2433; Found: 328.2405.
- Murata, Y., Inomata, K., Kinoshita, H. and Tokate, H., *Bull. Chem. Soc. Jpn.*, **1983**, *56*, 2534.
- Data for compound **4**: ¹H NMR (400 MHz, CDCl₃, rapamycin numbering): δ (ppm): 71.7 and 6.84 (2H, 2d, *J* = 8.3 Hz, Ar-H), 5.76 (1H, d, *J* = 9, C₃₀-H), 4.53 (1H, d, *J* = 3, C₂₂-H), 4.35 (1H, m, C₃₄-H), 4.20 and 4.11 (2H, 2d, *J* = 10, CH₂-Ar), 3.97 (1H, d, *J* = 8, C₂₈-H), 3.79 (3H, s, OMe), 3.71 (1H, m, probably OH), 3.68 (1H, d, *J* = 7, C₂₆-H), 3.40 (3H, s, OMe), 3.39 (1H, partially obscured m, C₃₉-H), 3.28 (3H, s, OMe), 3.25 (3H, s, OMe), 3.30 (1H, masked d, C₂₇-H), 2.91 (1H, dt, C₄₀-H), 2.32-2.22 (3H, m, C₃₁-H and C₃₃-H x 2), 2.05 (1H, m, one of C₃₈-H), 1.88 (2H, m, C₂₃-H and C₂₅-H), 1.76 (2H, m, C₃₅-H and one of C₄₁-H), 1.55 (3H, d, *J* = 0.8, C₂₉-Me), 1.60-1.36 (5H, m, one of C₂₄-H, C₃₆-H x 2, C₃₇-H and one of C₄₂-H), 1.28-1.12 (2H, m, one of C₂₄-H and one of C₄₁-H), 0.95 (3H, d, *J* = 7, C₃₅-Me), 0.91 (1H, masked m, one of C₄₂-H), 0.88 (18H, broad s, ^tBuSi, C₂₃-Me, C₂₅-Me and C₃₁-Me), 0.83 (1H, masked m, one of C₃₈-H), 0.07 and 0.06 (6H, 2s, Me₂Si); the presence of the ketone function is further confirmed by a signal at 216.3 ppm on the ¹³C spectrum (50 MHz, CDCl₃); Mass (FAB): *m/z*: 763 (MH⁺), 744 (M- H₂O), 655, 637, 623, 605, 591, 587, 467, 437; HRMS calculated for C₄₃H₇₅O₉Si (MH⁺): Calcd: 763.5180; found: 763.5187.

(Received in UK 2 December 1993; revised 18 January 1994; accepted 28 January 1994)